Clinical trial
Adjuvant Epirubicin/Cytoxan Followed By A Taxane VS. Epirubicin/Taxane As…
NCT00140075 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00140075 |
|---|---|
| Title | Adjuvant Epirubicin/Cytoxan Followed By A Taxane VS. Epirubicin/Taxane As Treatment For Node-Positive Breast Cancer |
| Official title | Phase III, Randomized Study Of Epirubicin/Cyclophosphamide Followed By Taxane (Sequential Chemotherapy) Versus Epirubicin/Taxane (Concurrent Chemotherapy) As Adjuvant Treatment For Operable, Node-Positive Breast Cancer |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Adenocarcinoma |
| Intervention type | Drug |
| Interventions | Epirubicin with Cyclophosphamide, followed by a Taxane, Epirubicin with a Taxane |
| Enrollment | 606 |
| Start date | Nov 1, 2000 |
| Primary completion | Aug 1, 2006 |
| Completion | Aug 1, 2006 |
| First posted | Aug 31, 2005 |
| Last update posted | May 26, 2011 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: